Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Aoxing Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:
AOXG's Debt-to-EBITDA is not ranked *
in the Diversified Financial Services industry.
Industry Median: 5.845 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Aoxing Pharmaceutical Co Debt-to-EBITDA Related Terms
Aoxing Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AOXG vs OWCP, BSPK, MYHI: Debt-to-EBITDA Comparison
For the Shell Companies subindustry, Aoxing Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aoxing Pharmaceutical Co Debt-to-EBITDA vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Aoxing Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aoxing Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2017) EBITDA data.
Aoxing Pharmaceutical Co (AOXG) has a Debt-to-EBITDA of 6.18 as of Mar. 2017. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aoxing Pharmaceutical Co.
Is Aoxing Pharmaceutical Co's Debt-to-EBITDA too high?
Aoxing Pharmaceutical Co's current Debt-to-EBITDA is 6.18. The Diversified Financial Services industry median Debt-to-EBITDA is 5.85. Aoxing Pharmaceutical Co's value of 6.18 is 5.7% above this industry median.
How does Aoxing Pharmaceutical Co's Debt-to-EBITDA compare to OWCP and BSPK?
Aoxing Pharmaceutical Co's Debt-to-EBITDA of 6.18 can be compared against companies in the Diversified Financial Services industry. The industry median Debt-to-EBITDA is 5.85. Aoxing Pharmaceutical Co's value of 6.18 is 5.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Diversified Financial Services company?
The median Debt-to-EBITDA among Diversified Financial Services companies is 5.85, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aoxing Pharmaceutical Co's current Debt-to-EBITDA of 6.18 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aoxing Pharmaceutical Co. For the Diversified Financial Services industry, the median Debt-to-EBITDA is 5.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aoxing Pharmaceutical Co's current Debt-to-EBITDA is 6.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aoxing Pharmaceutical Co stock overvalued right now?
Aoxing Pharmaceutical Co (AOXG) has a current Debt-to-EBITDA of 6.18. The current Debt-to-EBITDA is 6.18 and 5.7% above the Diversified Financial Services industry median of 5.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aoxing Pharmaceutical Co (AOXG), the current Debt-to-EBITDA is 6.18 as of Mar. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aoxing Pharmaceutical Co Inc does not have any business operations and is restructuring for a new business model and plans to acquire an operating company via reverse merger.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AOXG has been successfully added to your 
